Altogether, through its multiple effects on different PCa-relevant oncogenes/pathways, i.e., ERK1/2, PI3K, c-myc and c-src, GP88 appears to be an interesting target in PCa treatment. The gene discussed is GRN; the disease is posterior cortical atrophy.